20-Apr-2026
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
Seeking Alpha News (Mon, 20-Apr 11:55 AM ET)
The 10 Healthcare stocks with the lowest forward P/E ratios
Seeking Alpha News (Thu, 16-Apr 4:39 PM ET)
Organon gains as Sun Pharma, Grünenthal said to seek takeover deals
Seeking Alpha News (Thu, 16-Apr 9:06 AM ET)
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
Business Wire (Thu, 16-Apr 7:30 AM ET)
Business Wire (Wed, 15-Apr 7:30 AM ET)
Business Wire (Fri, 27-Mar 8:00 AM ET)
Business Wire (Fri, 27-Feb 8:00 AM ET)
Business Wire (Mon, 23-Feb 7:30 AM ET)
PRNewswire (Mon, 16-Feb 5:31 PM ET)
Organon Maintains Stable Revenue and Margin Guidance Amid Shifting Market Dynamics
Market Chameleon (Thu, 12-Feb 2:59 AM ET)
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Organon & Co. Common trades on the NYSE stock market under the symbol OGN.
As of April 20, 2026, OGN stock price declined to $9.26 with 6,963,818 million shares trading.
OGN has a beta of 2.03, meaning it tends to be more sensitive to market movements. OGN has a correlation of 0.17 to the broad based SPY ETF.
OGN has a market cap of $2.41 billion. This is considered a Mid Cap stock.
Last quarter Organon & Co. Common reported $2 billion in Revenue and $.63 earnings per share. This fell short of revenue expectation by $-17 million and missed earnings estimates by -$.09.
In the last 3 years, OGN traded as high as $24.79 and as low as $5.69.
The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, FXH, IJS.
OGN has underperformed the market in the last year with a return of -16.0%, while the SPY ETF gained +36.0%. In the last 3 month period, OGN fell short of the market, returning -1.9%, while SPY returned +4.9%. However, in the most recent 2 weeks OGN has outperformed the stock market by returning +53.1%, while SPY returned +7.6%.
OGN support price is $9.26 and resistance is $10.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.